PrP systemic amyloidosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Feb 2014

NORTHERA: FDA approved

Treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Myobloc

Soltice Neurosciences, LLC

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Myobloc

(Botulinum toxin type B)Orphan drugstandard

Soltice Neurosciences, LLC

Acetylcholine Release Inhibitor [EPC]

12.1 Mechanism of Action MYOBLOC blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release o...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for PrP systemic amyloidosis.
Search all trials →
Search clinical trials for PrP systemic amyloidosis

Recent News & Research

No recent news articles indexed yet for PrP systemic amyloidosis.
Search PubMed for PrP systemic amyloidosis

Browse all PrP systemic amyloidosis news →

Specialist Network

No specialists currently listed for PrP systemic amyloidosis.

View all PrP systemic amyloidosis specialists →

Quick Actions